Elite Pharmaceuticals ELTP Stock
Elite Pharmaceuticals Price Chart
Elite Pharmaceuticals ELTP Financial and Trading Overview
| Elite Pharmaceuticals stock price | 0.28 USD |
| Previous Close | 0.3 USD |
| Open | 0.3 USD |
| Bid | 0.29 USD x 250000 |
| Ask | 0.29 USD x 250000 |
| Day's Range | 0.29 - 0.3 USD |
| 52 Week Range | 0.27 - 0.74 USD |
| Volume | 337.72K USD |
| Avg. Volume | 698.04K USD |
| Market Cap | 312.37M USD |
| Beta (5Y Monthly) | 0.398 |
| PE Ratio (TTM) | 5.7999997 |
| EPS (TTM) | 0.05 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ELTP Valuation Measures
| Enterprise Value | 278.03M USD |
| Trailing P/E | 5.7999997 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.215162 |
| Price/Book (mrq) | 2.9896905 |
| Enterprise Value/Revenue | 1.972 |
| Enterprise Value/EBITDA | 7.452 |
Trading Information
Elite Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.398 |
| 52-Week Change | -47.27% |
| S&P500 52-Week Change | 18.35% |
| 52 Week High | 0.74 USD |
| 52 Week Low | 0.27 USD |
| 50-Day Moving Average | 0.36 USD |
| 200-Day Moving Average | 0.41 USD |
ELTP Share Statistics
| Avg. Volume (3 month) | 698.04K USD |
| Avg. Daily Volume (10-Days) | 1.33M USD |
| Shares Outstanding | 1.08B |
| Float | 836.08M |
| Short Ratio | 0.87 |
| % Held by Insiders | 22.37% |
| % Held by Institutions | 0% |
| Shares Short | 1.61M |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 2.16% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | March 31, 2027 |
Profitability
| Profit Margin | 40.18% |
| Operating Margin (ttm) | 23.27% |
| Gross Margin | 43.47% |
| EBITDA Margin | 26.45% |
Management Effectiveness
| Return on Assets (ttm) | 17.82% |
| Return on Equity (ttm) | 74.31% |
Income Statement
| Revenue (ttm) | 141.01M USD |
| Revenue Per Share (ttm) | 0.13 USD |
| Quarterly Revenue Growth (yoy) | -19.50% |
| Gross Profit (ttm) | 61.31M USD |
| EBITDA | 37.31M USD |
| Net Income Avi to Common (ttm) | 56.67M USD |
| Diluted EPS (ttm) | 0.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 38.94M USD |
| Total Cash Per Share (mrq) | 0.04 USD |
| Total Debt (mrq) | 5.57M USD |
| Total Debt/Equity (mrq) | 5.32 USD |
| Current Ratio (mrq) | 3.761 |
| Book Value Per Share (mrq) | 0.097 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 19.04M USD |
| Levered Free Cash Flow (ttm) | 23M USD |
Profile of Elite Pharmaceuticals
| Country | United States |
| State | NJ |
| City | Northvale |
| Address | 165 Ludlow Avenue |
| ZIP | 07647 |
| Phone | 201 750 2646 |
| Website | https://www.elitepharma.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 65 |
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. It also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; Methotrexate Sodium 2.5mg tablets for the treatment of Antimetabolite under the Otrexup PF brand; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; Acetaminophen and Hydrocodone Bitartrate capsules for the treatment of pain under the Norco brand; Lisdexamfetamine Dimesylate to treat ADHD under the Vyvanse brand; Oxycodone Hydrochloride and Acetaminophen tablets to treat pain under the Percocet brand name; and Methadone Hydrochloride tablets for the treatment of pain under the Dolophine brand. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of allergy, bariatric, attention deficit, and infection. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
Q&A For Elite Pharmaceuticals Stock
What is a current ELTP stock price?
Elite Pharmaceuticals ELTP stock price today per share is 0.28 USD.
How to purchase Elite Pharmaceuticals stock?
You can buy ELTP shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Elite Pharmaceuticals?
The stock symbol or ticker of Elite Pharmaceuticals is ELTP.
Which industry does the Elite Pharmaceuticals company belong to?
The Elite Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.
How many shares does Elite Pharmaceuticals have in circulation?
The max supply of Elite Pharmaceuticals shares is 1.08B.
What is Elite Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Elite Pharmaceuticals PE Ratio is 5.68600000 now.
What was Elite Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Elite Pharmaceuticals EPS is 0.05 USD over the trailing 12 months.
Which sector does the Elite Pharmaceuticals company belong to?
The Elite Pharmaceuticals sector is Healthcare.


